Genmab Statistics
Total Valuation
Genmab has a market cap or net worth of $12.93 billion. The enterprise value is $10.63 billion.
Important Dates
The last earnings date was Wednesday, November 6, 2024.
| Earnings Date | Nov 6, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Genmab has 63.51 million shares outstanding. The number of shares has decreased by -1.23% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 63.51M |
| Shares Change (YoY) | -1.23% |
| Shares Change (QoQ) | -1.51% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 62.84M |
Valuation Ratios
The trailing PE ratio is 18.39 and the forward PE ratio is 19.86.
| PE Ratio | 18.39 |
| Forward PE | 19.86 |
| PS Ratio | n/a |
| Forward PS | 0.58 |
| PB Ratio | n/a |
| P/TBV Ratio | 4.80 |
| P/FCF Ratio | 13.92 |
| P/OCF Ratio | 12.85 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 10.37, with an EV/FCF ratio of 11.45.
| EV / Earnings | 15.12 |
| EV / Sales | 3.58 |
| EV / EBITDA | 10.37 |
| EV / EBIT | 10.83 |
| EV / FCF | 11.45 |
Financial Position
The company has a current ratio of 5.17, with a Debt / Equity ratio of 0.03.
| Current Ratio | 5.17 |
| Quick Ratio | 5.15 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | 0.14 |
| Debt / FCF | 0.16 |
| Interest Coverage | 149.16 |
Financial Efficiency
Return on equity (ROE) is 14.92% and return on invested capital (ROIC) is 12.66%.
| Return on Equity (ROE) | 14.92% |
| Return on Assets (ROA) | 10.95% |
| Return on Capital (ROIC) | 12.66% |
| Revenue Per Employee | $1.35M |
| Profits Per Employee | $319,077 |
| Employee Count | 2,204 |
| Asset Turnover | 0.53 |
| Inventory Turnover | 10.98 |
Taxes
In the past 12 months, Genmab has paid $279.23 million in taxes.
| Income Tax | 279.23M |
| Effective Tax Rate | 28.42% |
Stock Price Statistics
The stock price has decreased by -37.65% in the last 52 weeks. The beta is 0.86, so Genmab's price volatility has been lower than the market average.
| Beta (5Y) | 0.86 |
| 52-Week Price Change | -37.65% |
| 50-Day Moving Average | 23.40 |
| 200-Day Moving Average | 26.95 |
| Relative Strength Index (RSI) | 25.28 |
| Average Volume (20 Days) | 1,496,932 |
Short Selling Information
| Short Interest | 2.34M |
| Short Previous Month | 1.90M |
| Short % of Shares Out | 0.37% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 1.84 |
Income Statement
In the last 12 months, Genmab had revenue of $2.97 billion and earned $703.24 million in profits. Earnings per share was $10.80.
| Revenue | 2.97B |
| Gross Profit | 2.85B |
| Operating Income | 981.58M |
| Pretax Income | 1.09B |
| Net Income | 703.24M |
| EBITDA | 1.03B |
| EBIT | 981.58M |
| Earnings Per Share (EPS) | $10.80 |
Full Income StatementBalance Sheet
The company has $2.59 billion in cash and $147.62 million in debt, giving a net cash position of $2.44 billion or $38.46 per share.
| Cash & Cash Equivalents | 2.59B |
| Total Debt | 147.62M |
| Net Cash | 2.44B |
| Net Cash Per Share | $38.46 |
| Equity (Book Value) | 4.77B |
| Book Value Per Share | 75.17 |
| Working Capital | 2.86B |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $1.01 billion and capital expenditures -$23.93 million, giving a free cash flow of $928.97 million.
| Operating Cash Flow | 1.01B |
| Capital Expenditures | -23.93M |
| Free Cash Flow | 928.97M |
| FCF Per Share | $14.63 |
Full Cash Flow StatementMargins
Gross margin is 96.10%, with operating and profit margins of 33.07% and 23.69%.
| Gross Margin | 96.10% |
| Operating Margin | 33.07% |
| Pretax Margin | 33.10% |
| Profit Margin | 23.69% |
| EBITDA Margin | 34.54% |
| EBIT Margin | 33.07% |
| FCF Margin | 35.02% |
Dividends & Yields
Genmab does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 1.23% |
| Shareholder Yield | 1.23% |
| Earnings Yield | 5.44% |
| FCF Yield | 7.18% |
Dividend DetailsAnalyst Forecast
The average price target for Genmab is $43.00, which is 110.27% higher than the current price. The consensus rating is "Buy".
| Price Target | $43.00 |
| Price Target Difference | 110.27% |
| Analyst Consensus | Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (5Y) | 17.83% |
| EPS Growth Forecast (5Y) | 23.66% |
Stock ForecastsStock Splits
The last stock split was on May 1, 2018. It was a forward split with a ratio of 5:1.
| Last Split Date | May 1, 2018 |
| Split Type | Forward |
| Split Ratio | 5:1 |
Scores
Genmab has an Altman Z-Score of 12.28 and a Piotroski F-Score of 6.
| Altman Z-Score | 12.28 |
| Piotroski F-Score | 6 |